Should I Buy IPHA? IPHA 2026 Analysis

Should You Buy Innate Pharma SA (IPHA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.740

1 Day change

4.82%

52 Week Range

2.630

Analysis Updated At

2026/02/13

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Innate Pharma SA (IPHA) is not a good buy at the moment for a beginner investor with a long-term strategy. The technical indicators are bearish, there are no positive trading signals, and no recent news or catalysts to suggest a strong upside. Additionally, there is no financial data or valuation information available to support a confident investment decision.

Technical Analysis

The MACD is negatively expanding, RSI is neutral at 29.092, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 1.768, with resistance at 1.855 and support at 1.68. Overall, the technical indicators suggest a bearish trend.

Positive Catalysts

NULL identified. No recent news or significant trading trends to suggest a positive catalyst.

Neutral/Negative Catalysts

Bearish technical indicators, lack of trading signals, and no significant insider or hedge fund activity.

Financial Performance

No financial data available for analysis. Latest quarter financials could not be assessed due to missing data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available for IPHA.

2 Analyst Rating

Wall Street analysts forecast IPHA stock price to rise

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.660

Low

Averages

6.5

High

Current: 1.660

Low

Averages

6.5

High

H.C. Wainwright

Neutral -> Buy

upgrade

AI Analysis

2025-10-29

Reason

H.C. Wainwright

Price Target

AI Analysis

2025-10-29

upgrade

Neutral -> Buy

Reason

H.C. Wainwright upgraded Innate Pharma to Buy from Neutral with a $5 price target. The company announced its intention to file an application with the FDA for an accelerated approval of lacutamab and initiate a Phase 3 study to evaluate the drug as a therapy for cutaneous T-cell lymphoma, the analyst tells investors in a research note. The firm recommends buying the stock's recent weakness.

Lucid Capital

NULL

Buy

initiated

2025-10-23

Reason

Lucid Capital

Price Target

2025-10-23

initiated

NULL

Buy

Reason

Lucid Capital initiated coverage of Innate Pharma with a Buy rating and $8 price target. Innate is a clinical-stage biotechnology company focused on developing antibodies and antibody-drug conjugates for oncology indications, the analyst tells investors in a research note. The firm believes the company's IPH4502 could serve a "key niche" in Padcev-pretreated metastatic urothelial carcinoma, a $1.5B peak sales opportunity.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IPHA

Unlock Now

IPHA Should I Buy

IPHA Should I Buy

Should You Buy Innate Pharma SA (IPHA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch